Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

Bristol Myers Squibb announced positive topline results from its registrational Phase 2 QUINTESSENTIAL trial for a CAR T-cell therapy program. The headline supports the program's clinical and regulatory trajectory, although the article provides no efficacy, safety, or financial details to quantify the result's commercial significance.